ClinicalTrials.gg
RecruitingNCT07720284TU-04Updated Jul 22, 2026

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

A Phase 3 interventional study of Dato-DXd and Rilvegostomig in High-risk Muscle Invasive Urothelial Carcinoma, sponsored by AstraZeneca. Recruiting at 160 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
915
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 88 studies in Carcinoma, Transitional Cell with a site in China — 51 open to participants now, 56 under way, 9 of them phase 3. Carcinoma, Transitional Cell · China.

Planned enrollment
3rd of 69
915 · median 60
Started
2026
with 18 others
Phase 3
11 of 88
5 open now
Primary completion
2030-09
later than 54 of 55 live
Registered
84th of 88
by date

Among the 88 studies in Carcinoma, Transitional Cell with a site in China, this one is the 3rd largest by planned enrollment of the 69 interventional ones that give a count, is one of 19 that started in 2026, is one of 11 in phase 3, reaches primary completion later than 54 of the 55 other live ones, and was the 84th registered.

Carcinoma, Transitional Cell

632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

51 of the 88 studies in Carcinoma, Transitional Cell with a site in China are open now. Recruiting first, the newest first:

45 more — sign in →

All 51 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Carcinoma, Transitional Cell with a site in China, or all of them as a file.
02

Study summary

Purpose: to assess efficacy and safety of Dato-DXd + rilvegostomig as adjuvant therapy versus SoC in MIUC participants with high-risk residual disease after radical resection.

Study details:

Duration: \~78 months (6.5 years) from FSI to last subject visit Treatment length: up to \~12 months, depending on randomized arm Visit frequency: every 3 weeks in Arms 1 and 2; every 2-4 weeks per SoC in Arm 3

03

Conditions studied

  • High-risk Muscle Invasive Urothelial Carcinoma

Keywords

  • Urothelial Carcinoma
  • Carcinoma
  • Datopotamab deruxtecan
  • Dato-DXd
  • DS-1062a
  • Rilvegostomig
  • AZD2936
  • Invasive Urothelial Carcinoma
  • Muscle Invasive Urothelial Carcinoma
  • High-risk MIUC
  • Adjuvant Urothelial Cancer
  • Bladder cancer
  • UTUC
  • Trop2. directed ADC
  • Immunotherapy
  • phase III
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be > 18 years of age at the time of signing the ICF.
  2. confirmed MIUC of the bladder or upper tract.
  3. Completed R0 radical resection 28 to 120 days before randomisation, with negative margins and no residual or disease.
  4. Pathologic evidence of urothelial carcinoma at high-risk of recurrence and

    1. not received therapy and has pT3-pT4aN0, or any pT with pN+ stage
    2. completed neoadjuvant treatment and has ypT2-ypT4a, or any ypT with ypN+ stage
  5. No evidence of disease at screening,
  6. performance status of 0 or 1 with no deterioration over the previous 2 weeks prior to randomisation.
  7. Minimum of > 12 weeks at time of screening.
  8. An archival surgical tumour sample must be available pre-randomisation for central testing.
  9. Adequate organ and bone marrow function within 28 days before randomisation.

Exclusion criteria

Exclusion criteria:

  1. Any tumour with predominant or pure high grade neuroendocrine carcinoma component.
  2. Partial cystectomy in the setting of bladder cancer primary tumour or partial nephrectomy.
  3. Any systemic or radiation therapy post-surgery for urothelial carcinoma.
  4. Severe or uncontrolled systemic diseases, history of organ transplant or stem cell transplant, or psychological disorders/social situations, and/or substance abuse.
  5. History of corneal disease.
  6. History of another primary except for malignancy treated with curative intent with no known active disease within 2 years before the first dose of study intervention and of low potential risk for recurrence.
  7. Ongoing toxicities except alopecia from prior cancer treatment must be Grade ≤ 1 or at baseline. Stable Grade 2 toxicities are allowed if unchanged for ≥3 months and managed by standard care.
  8. Active or uncontrolled or C virus infection.
  9. Known infection that is not well controlled.
  10. Any other active or uncontrolled infection including tuberculosis requiring systemic treatment that has not resolved by the time of randomisation.
  11. History of non-infectious ILD/pneumonitis including radiation, pneumonitis that required , has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
  12. Has clinically severe pulmonary function compromise.
  13. Mean resting corrected > 470 ms regardless of gender, obtained from triplicate 12-lead ECGs performed at screening
  14. Uncontrolled or significant cardiac conditions.
  15. Active or prior documented or inflammatory disorders requiring systemic treatment in the past 5 years.
  16. Prior exposure to TROP2-directed therapies, other ADCs with deruxtecan, therapeutic anti-cancer vaccines, anti-TIGIT therapy or any other anti-cancer therapy targeting immune-regulatory receptors or mechanisms.
  17. Current or prior use of medication within 14 days prior to treatment assignment/randomisation.
  18. Known history of severe reactions to any study drug
  19. Not eligible to receive at least one of SoC according to local regulations/approvals.
  20. Currently pregnant (confirmed with positive pregnancy test), breastfeeding or planning to become pregnant.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
915 participants (estimated)

Study arms

  • Experimental
    Arm 1: Dato-DXd + rilvegostomig

    Dato-DXd: 6 mg/kg IV Q3W for 9 cycles (approximately 6 months), can be extended based on Investigator assessment of tolerability up to 17 cycles or up to 1 year + rilvegostomig: 750 mg IV Q3W 17 cycles or up to 1 year whichever occurs first.

    Drug: Dato-DXd · Drug: Rilvegostomig

  • Experimental
    Arm 2: Dato-DXd monotherapy

    Dato-DXd: 6 mg/kg IV Q3W for 9 cycles (approximately 6 months), can be extended based on Investigator assessment of tolerability up to 17 cycles or up to 1 year.

    Drug: Dato-DXd

  • Active comparator
    Arm 3 (SoC): nivolumab or durvalumab or EV + pembrolizumab

    Either: Nivolumab: 240 mg IV Q2W OR 480 mg IV Q4W up to 1 year Or: Durvalumab: 1500 mg IV Q4W for 8 cycles (or at a dose of 20 mg/kg Q4W in participants who weigh ≤ 30 kg) Or: EV 1.25 mg/kg D1, D8 Q3W up to 6 cycles + pembrolizumab 200 mg IV Q3W up to 14 cycles or 400 mg IV Q6W up to 7 cycles.

    Drug: Durvalumab · Drug: Nivolumab · Drug: Pembrolizumab · Drug: Enfortumab vedotin

Interventions

  • Dato-DXd is an ADC comprised of a recombinant humanised anti-TROP2 IgG1 mAb, MAAP-9001a, which is covalently conjugated via a cleavable drug-linker, MAAA1162a (the complex of MAAA-1181a and a maleimide tetrapeptide linker), using thioether bonds to the topoisomerase I inhibitor DXd.

    Also known as: Datopotamab deruxtecan, (Dato-DXd, DS-1062a)

  • Rilvegostomig is a monovalent, bispecific, humanised, IgG1 mAb engineered with an Fc domain that carries a triple mutation (L234F/L235E/P331S) designed to reduce Fc-mediated effector functions. Rilvegostomig contains 2 distinct paratopes that bind to human TIGIT and PD-1 and inhibit binding to their respective immuno-suppressive ligands.

    Also known as: AZD2936

  • A fully human monoclonal antibody that blocks the PD-L1 checkpoint to restore anti-tumor T-cell activity. Durvalumab is approved for Muscle invasive bladder cancer (MIBC) as perioperative regime.

    Also known as: Imfinzi, MEDI4736

  • A fully human monoclonal antibody against PD-1, promoting anti-tumor immunity. Approved across many malignancies such as melanoma, NSCLC, renal cell carcinoma, Hodgkin lymphoma, hepatocellular carcinoma, and colorectal cancer (dMMR/MSI-H), often alone or with ipilimumab. It's used in several cancers, notably unresectable stage III non-small cell lung cancer after chemoradiation and extensive-stage small cell lung cancer in combination regimens, among others, and is also approved for patients with muscle-invasive urothelial carcinoma (MIUC) at high risk of recurrence in the adjuvant setting.

    Also known as: OPDIVO®, BMS-936558

  • A humanized monoclonal antibody targeting PD-1, enhancing T-cell-mediated immune responses against tumors. Indications span multiple cancers including melanoma, NSCLC, head and neck squamous cell carcinoma, urothelial carcinoma, MSI-H/dMMR tumors, and more.

    Also known as: Keytruda, MK-3475

  • An antibody-drug conjugate (ADC) comprised of a fully human anti-Nectin-4 IgG1 monoclonal antibody, linked via a protease-cleavable maleimide-based linker to the microtubule-disrupting agent monomethyl auristatin E (MMAE), which is conjugated through thioether bonds. Upon binding to Nectin-4-expressing cells, the ADC is internalized and releases MMAE, leading to disruption of microtubule dynamics and subsequent tumor cell death. Enfortumab vedotin is approved in urothelial cancers.

    Also known as: Padcev®, ASG-22CE, AGS-22M6E

06

What researchers measure

Primary outcomes

  1. To demonstrate the superiority of Dato-DXd + rilvegostomig (Arm 1) relative to SoC (Arm 3) by assessment of disease-free survival (DFS) (based on Investigator assessments).

    DFS is defined as the time from randomisation until disease recurrence (local urothelial tract, local non urothelial tract or distant) per RECIST 1.1 as assessed by Investigator, or death due to any cause. The analysis will include all randomised participants as randomised. All events will be included, regardless of whether the participant discontinues study treatment or receives another anti-cancer therapy. The measure of interest is the HR of DFS.

    Time frame: From randomisation until disease recurrence as assessed by investigator or death due to any cause (anticipated to be up to 49 months after the first subject in).

Secondary outcomes

  1. To demonstrate the superiority of Dato-DXd + rilvegostomig (Arm 1) relative to SoC (Arm 3) by assessment of OS (Overall survival).

    OS defined as the time from randomisation until the date of death due to any cause. The analysis will include all randomised participants as randomised. All deaths will be included regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy. The measure of interest is the HR of OS.

    Time frame: OS is defined as the time from randomisation until the date of death due to any cause, up to 78 months from first subject in.

  2. To demonstrate the superiority of Dato-DXd + rilvegostomig (Arm 1) relative to SoC (Arm 3) by assessment of DFS (based on Blinded Independent Central Review [BICR] assessments).

    DFS is defined as the time from randomisation until disease recurrence (local urothelial tract, local non urothelial tract or distant) per RECIST 1.1 as assessed by BICR, or death due to any cause. The analysis will include all randomised participants as randomised. All events will be included, regardless of whether the participant discontinues study treatment or receives another anti-cancer therapy. The measure of interest is the HR of DFS.

    Time frame: From randomisation until disease recurrence as assessed by BICR or death due to any cause (anticipated to be up to 49 months after the first subject in).

  3. To estimate the effectiveness of Dato-DXd monotherapy (Arm 2) versus SoC (Arm 3) and effectiveness of Dato-DXd in combination with rilvegostomig (Arm 1) versus Dato-DXd monotherapy (Arm 2) by assessment of OS.

    OS defined as the time from randomisation until the date of death due to any cause. The analysis will include all randomised participants as randomised. All deaths will be included regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy. The measure of interest is the HR of OS.

    Time frame: OS is defined as the time from randomisation until the date of death due to any cause, up to 78 months from first subject in.

  4. To estimate the effectiveness of Dato-DXd monotherapy (Arm 2) versus SoC (Arm 3) and effectiveness of Dato-DXd in combination with rilvegostomig (Arm 1) versus Dato-DXd monotherapy (Arm 2) by assessment of DFS based on Investigator assessments.

    DFS is defined as the time from randomisation until disease recurrence (local urothelial tract, local non urothelial tract or distant) per RECIST 1.1 as assessed by Investigator, or death due to any cause. The analysis will include all randomised participants as randomised. All events will be included, regardless of whether the participant discontinues study treatment or receives another anti-cancer therapy. The measure of interest is the HR of DFS.

    Time frame: From randomisation until disease recurrence as assessed by investigator or death due to any cause (anticipated to be up to 49 months after the first subject in).

  5. To estimate the effectiveness of Dato-DXd monotherapy (Arm 2) versus SoC (Arm 3) and effectiveness of Dato-DXd in combination with rilvegostomig (Arm 1) versus Dato-DXd monotherapy (Arm 2) by assessment of DFS by BICR.

    DFS is defined as the time from randomisation until disease recurrence (local urothelial tract, local non urothelial tract or distant) per RECIST 1.1 as assessed by BICR, or death due to any cause. The analysis will include all randomised participants as randomised. All events will be included, regardless of whether the participant discontinues study treatment or receives another anti-cancer therapy. The measure of interest is the HR of DFS.

    Time frame: From randomisation until disease recurrence as assessed by BICR or death due to any cause (anticipated to be up to 49 months after the first subject in).

  6. To demonstrate effectiveness of Dato-DXd + rilvegostomig (Arm 1) vs SoC (Arm 3) by evaluating DSS (Disease specific survival), NUTRFS (Non-urothelial tract recurrence-free survival), DMFS (Distant metastasis free survival).

    DSS is defined as time from randomisation until death due to disease (urothelial cancer). The analysis will include all randomised participants as randomised. The measure of interest is the HR of DSS. NUTRFS is defined as time from randomisation until first local non-urothelial tract or distant recurrence or death due to any cause. The analysis will include all randomised participants as randomised. The measure of interest is the HR of NUTRFS. DMFS is defined as time from randomisation until first distant recurrence (non-local) or death due to any cause The analysis will include all randomised participants as randomised. The measure of interest is the HR of DMFS.

    Time frame: From randomisation up to 49 months after the first subject in.

Other outcomes

  1. To assess the pharmacokinetics (PK) of Dato-DXd and DXd, alone in the Dato-DXd monotherapy arm (Arm 2) and in combination with rilvegostomig (Arm 1). To assess the PK of rilvegostomig in Arm 1.

    Concentration of Dato-DXd and DXd in plasma. Concentration of rilvegostomig in serum.

    Time frame: Day 1 of Cycles 1, 2, 4, 5, and 8 (each cycle is 21 days), at the end of treatment (approximately up to 12 months after randomization), and at the end of safety follow-up (approximately up to 15 months after randomization).

  2. To investigate the immunogenicity of Dato-DXd and rilvegostomig in Dato-DXd + rilvegostomig combination therapy (Arm 1) and Dato-DXd monotherapy (Arm 2).

    Presence of antidrug antibody (ADA) for Dato-DXd in plasma and rilvegostomig in serum (confirmatory results: positive or negative, titres).

    Time frame: Day 1 of Cycles 1, 2, 4, 5, 6, 8, 10, and 14 (each cycle is 21 days), at the end of treatment (approximately up to 12 months after randomization), and at the end of safety follow-up (approximately up to 15 months after randomization).

  3. To assess participant-reported global health status (GHS)/quality of life (QoL) in participants treated with Dato-DXd + rilvegostomig (Arm 1) as compared with SoC (Arm 3).

    Proportion of participants with maintained or improved GHS/QoL as measured by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) GHS/QoL subscale (EORTC IL6) at each time point.

    Time frame: D1C1, then every 3w (21d cycles) until end of treatment (~12m from randomization); thereafter every 6w after treatment discontinuation until recurrence, start of subsequent therapy, or study discontinuation, up to 18m post-treatment.

  4. Safety of adjuvant Dato-DXd in combination with rilvegostomig as compared with Dato-DXd monotherapy and SoC.

    Safety will be evaluated in terms of AEs.

    Time frame: From randomization through the end of treatment (approximately up to 12 months after randomization) and through the end of safety follow-up (approximately up to 15 months after randomization).

07

Study locations

3 of 160 sites recruiting
  • Research Site
    Hot Springs, Arkansas 71913, United States
    Not yet recruiting
  • Research Site
    Little Rock, Arkansas 72205, United States
    Not yet recruiting
  • Research Site
    Little Rock, Arkansas 72211, United States
    Not yet recruiting
  • Research Site
    San Francisco, California 94143, United States
    Not yet recruiting
  • Research Site
    Chicago, Illinois 60637, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Boston, Massachusetts 02215, United States
    Not yet recruiting
  • Research Site
    Kansas City, Missouri 64132, United States
    Not yet recruiting
  • Research Site
    Lincoln, Nebraska 68506, United States
    Not yet recruiting
  • Research Site
    Omaha, Nebraska 68130, United States
    Not yet recruiting
  • Research Site
    Albany, New York 12208, United States
    Not yet recruiting
  • Research Site
    New York, New York 10065, United States
    Not yet recruiting
  • Research Site
    Cleveland, Ohio 44195, United States
    Not yet recruiting
  • Research Site
    Myrtle Beach, South Carolina 29572, United States
    Not yet recruiting
  • Research Site
    Nashville, Tennessee 37203, United States
    Not yet recruiting
  • Research Site
    Dallas, Texas 75235, United States
    Not yet recruiting
  • Research Site
    Falls Church, Virginia 22042, United States
    Not yet recruiting
  • Research Site
    Seattle, Washington 98109, United States
    Not yet recruiting
  • Research Site
    Tacoma, Washington 98405, United States
    Not yet recruiting
  • Research Site
    Milwaukee, Wisconsin 53226, United States
    Not yet recruiting
  • Research Site
    Auchenflower, 4066, Australia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Ballarat, 3350, Australia
    Not yet recruiting
  • Research Site
    Clayton, 3168, Australia
    Not yet recruiting
  • Research Site
    Darlinghurst, 2010, Australia
    Not yet recruiting
  • Research Site
    Elizabeth Vale, 5112, Australia
    Not yet recruiting
  • Research Site
    South Brisbane, 4101, Australia
    Not yet recruiting
  • Research Site
    St Albans, 3021, Australia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Barretos, 14784-400, Brazil
    Not yet recruiting
  • Research Site
    Curitiba, 81520-060, Brazil
    Not yet recruiting
  • Research Site
    Salvador, 41950-640, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, 01323-903, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, 05652-900, Brazil
    Not yet recruiting
  • Research Site
    Calgary, Alberta T2N 5G2, Canada
    Not yet recruiting
  • Research Site
    Abbotsford British Columbia, British Columbia V2S0C2, Canada
    Not yet recruiting
  • Research Site
    Barrie, Ontario L4M 6M2, Canada
    Recruiting
  • Research Site
    Hamilton, Ontario L8V 5C2, Canada
    Recruiting
  • Research Site
    Kingston, Ontario K7L 2V7, Canada
    Not yet recruiting
  • Research Site
    London, Ontario N6C 2R5, Canada
    Not yet recruiting
  • Research Site
    Mississauga, Ontario L5M 2N1, Canada
    Not yet recruiting
  • Research Site
    Montreal, Quebec H2X 0A9, Canada
    Not yet recruiting
  • Research Site
    Montreal, Quebec H3A 1A1, Canada
    Not yet recruiting
  • Research Site
    Beijing, 100034, China
    Not yet recruiting
  • Research Site
    Beijing, 100050, China
    Not yet recruiting
  • Research Site
    Beijing, 100191, China
    Not yet recruiting
  • Research Site
    Changsha, 410013, China
    Not yet recruiting
  • Research Site
    Chengdu, 610000, China
    Not yet recruiting
  • Research Site
    Chengdu, 610072, China
    Not yet recruiting
  • Research Site
    Chongqing, 400016, China
    Not yet recruiting
  • Research Site
    Chongqing, 400030, China
    Not yet recruiting
  • Research Site
    Fuzhou, 350005, China
    Not yet recruiting
  • Research Site
    Guangzhou, 510220, China
    Not yet recruiting
  • Research Site
    Guangzhou, 510288, China
    Not yet recruiting
  • Research Site
    Guiyang, 550044, China
    Not yet recruiting
  • Research Site
    Hangzhou, 310003, China
    Not yet recruiting
  • Research Site
    Hangzhou, 310009, China
    Not yet recruiting
  • Research Site
    Harbin, 150049, China
    Not yet recruiting
  • Research Site
    Jinan, 250012, China
    Not yet recruiting
  • Research Site
    Jinan, 250021, China
    Not yet recruiting
  • Research Site
    Kunming, 650101, China
    Not yet recruiting
  • Research Site
    Kunming, 650118, China
    Not yet recruiting
  • Research Site
    Lanzhou, 730030, China
    Not yet recruiting
  • Research Site
    Nanchang, 330006, China
    Not yet recruiting
  • Research Site
    Nanjing, 210008, China
    Not yet recruiting
  • Research Site
    Nanning, 530021, China
    Not yet recruiting
  • Research Site
    Ningbo, 315010, China
    Not yet recruiting
  • Research Site
    Qingdao, 266003, China
    Not yet recruiting
  • Research Site
    Shanghai, 200040, China
    Not yet recruiting
  • Research Site
    Shenyang, 110004, China
    Not yet recruiting
  • Research Site
    Shenyang, 110042, China
    Not yet recruiting
  • Research Site
    Suining Shi, 629000, China
    Not yet recruiting
  • Research Site
    Tianjin, 300211, China
    Not yet recruiting
  • Research Site
    Wenzhou, 325000, China
    Not yet recruiting
  • Research Site
    Wuhan, 430022, China
    Not yet recruiting
  • Research Site
    Wuhan, 430030, China
    Not yet recruiting
  • Research Site
    Xuzhou, 221000, China
    Not yet recruiting
  • Research Site
    Zhengzhou, 450008, China
    Not yet recruiting
  • Research Site
    Bordeaux, 33000, France
    Not yet recruiting
  • Research Site
    Montpellier, 34298, France
    Not yet recruiting
  • Research Site
    Paris, 75014, France
    Not yet recruiting
  • Research Site
    Pierre-Bénite, 69310, France
    Not yet recruiting
  • Research Site
    Poitiers, 86000, France
    Not yet recruiting
  • Research Site
    Strasbourg, 67098, France
    Not yet recruiting
  • Research Site
    Bochum, 44791, Germany
    Not yet recruiting
  • Research Site
    Bonn, 53127, Germany
    Not yet recruiting
  • Research Site
    Dresden, 01307, Germany
    Not yet recruiting
  • Research Site
    Duisburg, 47169, Germany
    Not yet recruiting
  • Research Site
    Frankfurt am Main, 60431, Germany
    Not yet recruiting
  • Research Site
    Hamburg, 20246, Germany
    Not yet recruiting
  • Research Site
    Hanover, 30625, Germany
    Not yet recruiting
  • Research Site
    Herne, 44625, Germany
    Not yet recruiting
  • Research Site
    Magdeburg, 39120, Germany
    Not yet recruiting
  • Research Site
    Mannheim, 68167, Germany
    Not yet recruiting
  • Research Site
    Marburg, 35043, Germany
    Not yet recruiting
  • Research Site
    Mettmann, 40822, Germany
    Not yet recruiting
  • Research Site
    Münster, 48149, Germany
    Not yet recruiting
  • Research Site
    Nuremberg, 90419, Germany
    Not yet recruiting
  • Research Site
    Nürtingen, 72622, Germany
    Not yet recruiting
  • Research Site
    Regensburg, 93053, Germany
    Not yet recruiting
  • Research Site
    Rostock, 18057, Germany
    Not yet recruiting
  • Research Site
    Stuttgart, 70174, Germany
    Not yet recruiting
  • Research Site
    Tübingen, 72076, Germany
    Not yet recruiting

Showing the first 100 of 160 sites across 16 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Informed consent form

Time frame: Study start to completion date

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Sep 2030, 49 months after the start.

Of 28 phase 3 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 111. This study's planned 49 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2026
First posted
Jul 22, 2026
StartActual
Jul 16, 2026
Primary completionEst.
Sep 11, 2030
CompletionEst.
Nov 23, 2032
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07720284
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Jul 22, 2026
Start date
Jul 16, 2026
Primary completion
Sep 11, 2030 (estimated)
Completion
Nov 23, 2032 (estimated)
Last update
Jul 22, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Datopotamab deruxtecan · Rilvegostomig

Start the discussion